To summarize established and emerging mechanistic evidence connecting Epstein-Barr virus (EBV) to systemic lupus erythematosus (SLE) and discuss therapeutic implications, highlighting the significance of this connection.
Key Findings:
SLE patients exhibit higher EBV seropositivity rates and increased viral loads compared to healthy individuals, as reported in multiple studies.
EBV-infected B cells in SLE are transcriptionally distinct and enhance autoreactive CD4+ T cell activation, supported by recent research.
Impaired immune response to EBV in SLE is linked to defects in EBV-specific CD8+ T cells and altered CD4+ T cell populations, necessitating further investigation.
Interpretation:
EBV is an active participant in lupus pathogenesis, contributing to immune dysregulation rather than being a passive bystander, with significant implications for understanding disease mechanisms.
Limitations:
The precise mechanisms linking EBV infection to lupus autoimmunity remain incompletely understood, warranting targeted research efforts.
Further research is needed to fully elucidate the role of EBV in SLE and its therapeutic implications, particularly in clinical settings.
Conclusion:
Emerging data position EBV-infected B cells as significant contributors to lupus pathogenesis, suggesting new avenues for therapeutic intervention that could transform patient care.
